statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs

Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage...

Why Humacyte Stock Is Trading 15% Higher Monday

Humacyte received the Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its Acellular Tissue Engineered Vessel.
read more...

Peering Into Humacyte's Recent Short Interest

How Is The Market Feeling About Humacyte?

Humacyte (NASDAQ:HUMA) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a research report released on Monday, Benzinga reports. They currently have a $7.00 price...

Humacyte (NASDAQ:HUMA) Earns Neutral Rating from Piper Sandler

Piper Sandler reiterated their neutral rating on shares of Humacyte (NASDAQ:HUMA  Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage...

Benchmark Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA)

Benchmark reissued their buy rating on shares of Humacyte (NASDAQ:HUMA  Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $15.00 price...

Humacyte to Host Virtual KOL Event  Hemodialysis Access: A Crossroads of Care,  on March 28, 2024

DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...

Humacyte (NASDAQ:HUMA) Posts  Earnings Results

Humacyte (NASDAQ:HUMA  Get Free Report) released its earnings results on Friday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of...

Q4 2023 Humacyte Inc Earnings Call Transcript

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Volume	3.88M
52-Wk High	$9.97
52-Wk Low	$1.96

HUMA Humacyte Inc

About

Feed

News

Sentiment

Earnings

Fundamentals